Alexander Belcredi is a seasoned professional with over a decade of experience in the pharmaceutical industry. Currently serving as the Managing Director of BioNTech’s anti-bacterial research department in Austria, he plays a pivotal role in advancing groundbreaking anti-bacterial research. In 2017, Alexander co-founded PhagoMed Biopharma GmbH, a biotech company dedicated to developing innovative phage-based pharmaceuticals for the treatment of bacterial infections. Serving as Co-CEO at PhagoMed, he successfully led the company to an acquisition by BioNTech in late 2021. Prior to his entrepreneurial venture, Alexander spent nine years at the Boston Consulting Group, providing strategic counsel to pharmaceutical and MedTech clients. He holds an MA in Modern History and Economics from the University of St. Andrews and an MBA from INSEAD.